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ABSTRACT 
A series of synthetic nicotinamide cofactors were synthesized to replace natural nicotinamide cofactors and promote 
enoate reductase (ER)-catalyzed reactions without compromising activity or stereoselectivity of the bioreduction 
process. Conversions and enantioselectivities of up to >99% were obtained for C=C bioreductions and the process 
was successfully upscaled. Furthermore, high chemoselectivity was observed when employing these nicotinamide 
cofactor mimics (mNADs) with crude extracts in ER-catalyzed reactions. 
The asymmetric reduction of conjugated C=C double 
bonds using enoate reductases (ERs, EC 1.3.1.31) is 
receiving great interest in preparative organic chemistry.
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Figur  1 
stereospecific reductions makes this method a viable 
alternative to transition metal-catalyzed reductions. New 
ERs are constantly added to the toolbox from natural 
sources
1d,2
 and obtained via protein engineering.
3
 These 
enzymes are en route to becoming truly practical 
catalysts, although one remaining challenge involves their 
dependency on reduced nicotinamide cofactors 
[NAD(P)H] providing the reducing equivalents needed 
for the alkene bioreduction. NAD(P)H is rather 
expensive,
4
 forbidding its stoichiometric use at high scale. 
In principle, this can be overcome by using an 
(enzymatic) cofactor regeneration system.
5
 
Another challenge resulting from the NAD(P)H-
dependency of ERs arises with conjugated aldehydes and 
ketones as starting materials. Here, frequently 
unsatisfactory chemoselectivity is observed unless highly 
purified, alcohol dehydrogenase (ADH)-free, enzyme 
preparations are used. The reason thereof lies in the 
overlap of the substrate scope for both enzyme classes. As 
a result, both substrates and products of the ER-catalyzed 
transformation can also be converted by ‘contaminating’ 
ADHs leading to complex product mixtures, impairing 
the overall chemoselectivity of the reactions.
1b,6
 
Substitution of NAD(P)H as a reducing agent by other 
reductants appears to be straightforward with ERs and 
may be the method of choice to circumvent the above-
mentioned challenges. Indeed, some promising 
approaches for NAD(P)H-independent regeneration have 
been reported recently.5
a,7
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We became interested in synthetic, functional mimics 
of the natural nicotinamide cofactors (mNAD, Scheme 1) 
as stoichiometric reductants to promote ER-catalyzed 
reduction reactions. 
 
Scheme 1. Asymmetric bioreduction of conjugated C=C double 
bonds using synthetic nicotinamide mimics (1-5)a and 6 
 
 
These mNADs are simple and cheap to synthesize, 
starting from commercially available pyridine derivatives 
(1,3-5)c; thus, the nitrogen was alkylated with benzyl or 
n-butyl bromide under reflux to obtain the bromide salts 
(1-5)b in high yields (81-92%), and the pyridinium ring 
was reduced into the corresponding dihydropyridine (1-
5)a in moderate to high yields (35-81%) with sodium 
dithionite and sodium bicarbonate (Scheme 2).  
 
Scheme 2. Straightforward two-step synthesis of the reduced 
nicotinamide mimics mNADs (1-5)a 
 
 
Synthetic mNADs have received considerable attention 
as cost-efficient alternatives to the natural NAD(P)H 
cofactors.
8
 Unfortunately, the catalytic efficiencies of the 
wild-type alcohol dehydrogenases with mNADs generally 
fall back by orders of magnitude below their activity with 
the natural cofactors.
9
 In that respect, ERs represent an 
exception as they exhibit significant ‘cofactor 
promiscuity’.7a-c In a first set of experiments, we 
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(9) This adds up in a biochemical sense as high specificity of 
enzymes for either phosphorylated or non-phosphorylated nicotinamide 
cofactors is essential for controlling cellular metabolism. 
evaluated the scope of enzymes accepting the mNAD 1a 
as a replacement for NAD(P)H. As a model reaction, we 
chose the reduction of ketoisophorone (7a) to the 
corresponding levodione product (7b) to assess the 
conversion as well as the enantioselectivity of the ER-
catalyzed reaction (Table 1). We were pleased to find that 
1a could replace the natural cofactors with a range of ERs 
without impairing the final yield or enantiospecificity of 
the reaction (entries 1-9). It is worth mentioning here that 
in the absence of either cofactor or enzyme no conversion 
was detectable within the time frame of the experiments. 
 
Table 1. Performance of 1a as a replacement for NADH or 
NADPH in the asymmetric bioreduction of ketoisophorone (7a) 
with different ERsa 
 
 
entry ERb cofactor conversion (%)c ee (%)c 
1 YqjM NADH 92 84 (R) 
2  NADPH 90 87 (R) 
3  1a 96 85 (R) 
4 TsER NADH 90 >95 (R) 
5  NADPH >99 >95 (R) 
6  1a >99 >95 (R) 
7 RmER NADH 76 95 (R) 
8  NADPH 73 95 (R) 
9  1a 72 96 (R) 
a Conditions: [substrate]0 = [cofactor]0 = 10 mM, [ER] = 90-200 
µg/mL, T = 30 ºC, reaction time: 4 h; b YqjM: ER from Bacillus 
subtilis,10 TsER: ER homologue from Thermus scotoductus,11 RmER: 
ER from Ralstonia metallidurans CH34; c determined by GC analysis. 
 
For further investigations the enoate reductase 
homologue from Thermus scotoductus (TsER) was 
used.
11
 As shown in Table 2, a broad range of different 
enones (entries 1-8), enals (entries 9-12) and maleimides 
(entries 13-16) could be converted in excellent yield and 
enantiospecificity demonstrating the preparative 
broadness of the ‘mimic-approach’. Currently, we are 
bringing the proposed bioreduction scheme to preparative 
scale. A first gram-scale reduction of N-phenyl-2-methyl 
maleimide (500 mM) gave excellent conversion and 
optical purities of the product (>99%) and acceptable 
isolated yields (>70%), showing the synthetic usefulness 
of this C=C reduction process to obtain enantioenriched 
compounds on a high scale. 
In order to obtain a more detailed insight into the 
reduction performance, the mNADs (1-5)a and 6 were 
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evaluated and compared to the natural cofactors (NADH 
and NADPH). 
 
Table 2. Substrate scope of 1a-driven chemoselective 
reductions of α,β-unsaturated carbonyl compounds (7-14)aa 
 
 
entry product cofactor conversion (%)b ee (%)b 
1 
2   7b 
NADH 
1a 
>99 
>99 
>95 (R) 
>95 (R) 
3 
4   8b 
NADH 
1a 
93 
82 
>99 (S) 
>99 (S) 
5 
6   9b 
NADH 
1a 
>99 
>99 
>99 (R) 
>99 (R) 
7 
8   10b 
NADH 
1a 
>99 
>99 
>99 (R) 
>99 (R) 
9 
10   11b 
NADH 
1a 
>99 
>99 
>99 (R) 
>99 (R) 
11 
12  12b 
NADH 
1a 
21 
18 
n.d.c 
n.d.c 
13 
14   13b 
NADH 
1a 
>99 
>99 
n.a.d 
n.a.d 
15 
16 
  14b 
NADH 
1a 
>99 
>99 
>99 (R) 
>99 (R) 
a Conditions: [substrate]0 = [cofactor]0 = 10 mM, [TsER] = 90 
µg/mL, T = 30 ºC, reaction time: 4 h; b Determined by GC analysis; c 
n.d. = not determined. d n.a. = not applicable. 
 
 
 
 
Figure 1. Comparison of enzymatic conversions for the 
reduction of ketoisophorone (7a) to (6R)-levodione (7b) 
catalyzed by TsER using different cofactors. Conditions: 
[ketoisophorone]0 = [cofactor]0 = 10 mM, [TsER] = 100 µg/mL 
= 2.2 M in MOPS buffer (50 mM, pH 7 with 5 mM CaCl2, 
containing 2% v/v MeOH in the case of (1-5)a and 6). 1a:, 
2a:, 3a:, 4a: , 5a: , 6: X, NADH: , NADPH: . 
 
Figure 1 shows the time courses of these bioreduction 
reactions. With the exception of the nitrile analogue (5a) 
and the Hantzsch ester (6), all synthetic nicotinamides 
exhibited equal or better activity with TsER. For example, 
initial rates obtained with 2a were 1.5-fold higher than 
with NADPH and almost double than with NADH. It is 
worth mentioning that the enantioselectivity in all cases 
was exclusive. The observed high activity of mimics (1-
4)a, even exceeding the activity of the natural cofactors, 
was somewhat unexpected, as with other enzyme classes 
investigated so far a significant decrease in activity had 
been observed. Molecular docking simulations of TsER 
with the mimics (Figure 2) confirmed the existence of 
productive binding modes for mimics 1a to 5a, leading to 
the reduced catalytically active FMNH2 species.
12
 
Interestingly, for the Hantzsch ester (6) only unproductive 
binding was observed, supporting the experimental 
observations. Possibly, the increased activity with mimics 
can be explained by an increased FMN-reduction rate. 
 
 
Figure 2. Exemplary result of docking 1a into the active site of 
TsER. 
 
Finally, we investigated the presumed chemoselectivity 
advantage of using NADH mimics over natural cofactors. 
For this, the product distribution in the reduction of citral 
(15) was compared using crude preparations of YqjM, 
recombinantly expressed in Escherichia coli. As shown in 
Table 3, using 1a as a reductant, the desired C=C double 
bond reduction product (citronellal, 16) was obtained as 
the sole product, while with NADH significant amounts 
of carbonyl reduction products (citronellol 18 and 
geraniol 17) were formed. 
Overall, we have demonstrated that cheap synthetic 
analogues of the natural nicotinamide cofactors (mNADs) 
represent a true alternative to the established regeneration 
systems to promote ER-catalyzed reduction reactions and 
apply them to preparative scale. Already under non-
optimized conditions, equal or higher conversions have 
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been obtained compared to those with the natural 
cofactors, without altering the selectivity. 
 
Table 3. Chemoselectivity of YqjM-crude extract-catalyzed 
reduction of citral (7) using NADH and 1a as stoichiometric 
reductant 
 
 
entry cofactor 16 (%)a 17 (%)a 18 (%)a Selectivity (%)b 
1 NADH 21 20 20 34 
2 1a 18 <1 <1 >90 
a Conversion determined by GC analysis.  b C=C double bond 
reduction over C=O bond reduction. 
 
Another very interesting opportunity with mNADs lies 
in the bioorthogonality
13
 of these reduction schemes. The 
very poor activity of most enzyme classes tested so far 
with mNADs (particularly alcohol dehydrogenases and 
monooxygenases) enable the use of poorly purified (and 
hence cheap) ER preparations without impairing the 
selectivity of the desired reactions. Admittedly, issues 
such as the in situ regeneration of catalytic amounts of 
mNADs and/or recycling will have to be addressed in 
order to fully exploit their catalytic potential. Also, more 
mechanistic and kinetic studies as well as further 
modeling will be necessary to understand the catalytic 
mechanism. These studies are currently underway in our 
laboratories, eventually leading to a truly practical 
approach for White Biotechnology. 
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